Acorda has deal with Danish drugmaker
-
- April
- 9
Acorda Therapeutics Inc. of Hawthorne said a Danish drug company will manufacture a key molecule in a substance that Acorda is using in toxicology studies and early phase clinical trials.
Acorda said the company, CMC ICOS Biologics of Copenhagen, will produce the molecule, GGF2, for Acorda’s neuregulin program. Terms of the deal were not announced. Neuregulins have the potential to be helpful in treatments for multiple sclerosis and stroke, Acorda said.
This entry was posted
on Wednesday, April 9th, 2008 at 12:44 pm by Jerry Gleeson.
You can follow any responses to this entry through the RSS 2.0 feed.
Share and Enjoy: 
| 
Print
| 
Email
Advertisement
